For the year ending 2025-12-31, ALUR had -$9,976K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | 15,230 | - | - |
| Cost of revenue | 5,659 | - | - |
| Sales and marketing | 10,804 | - | - |
| Research and development-Clinical Trials And Medical Affairs | 3,020 | - | - |
| Research and development-Product Development | 1,848 | - | - |
| Research and development-Digital | 969 | - | - |
| Unrealized exchange gain (loss) | - | -594 | - |
| Research and development-Quality And Regulatory | 1,733 | - | - |
| Change in fair value of derivative liabilities | - | 1,895 | -1,730 |
| General and administrative | 21,353 | - | - |
| Debt issuance costs associated with debt recorded at fair value | - | 1,357 | 1,210 |
| Other segment items | 1,401 | - | - |
| Non-cash termination of convertible note side letters | - | - | 16,098 |
| Net loss | -28,755 | -7,198 | -82,817 |
| Non-cash lease expense | 679 | 765 | 824 |
| Unrealized exchange gain | - | - | 180 |
| Change in fair value of debt | - | - | -3,751 |
| Depreciation and amortization | 983 | 997 | 746 |
| Stock-based compensation | 3,146 | 3,056 | 8,357 |
| Provision for uncollectible accounts | 2,847 | 1,418 | 12,675 |
| Unrealized exchange gain (loss) and other | 206 | - | - |
| Provision for inventory | 1,216 | 2,228 | 1,399 |
| Change in fair value of warrant liabilities | -12,800 | -17,024 | -8,364 |
| Change in fair value of debt | 3,615 | -18,090 | - |
| Change in fair value of revenue interest financing and pipe conversion option | -9,090 | -4,771 | -4,402 |
| Non-cash issuance of common stock for commitment shares | - | - | 123 |
| Change in fair value of earn-out liabilities | 1,059 | 22,900 | 29,050 |
| Non-cash interest expense | - | 1,464 | 2,083 |
| Change in fair value of rtw share obligation | 370 | - | - |
| Interest paid on debt recorded at fair value | 2,410 | 3,098 | 1,092 |
| Loss on extinguishment of debt | -660 | -8,713 | -3,929 |
| Issuance costs associated with warrants recorded at fair value | 1,502 | 942 | - |
| Accounts receivable | -844 | -8,977 | 1,318 |
| Inventory | 486 | -543 | 3,705 |
| Prepaid expenses, other current and long-term assets | -800 | -913 | -285 |
| Lease liabilities | -796 | -836 | -789 |
| Accounts payable | -3,141 | -3,924 | 4,664 |
| Accrued expenses and other current liabilities | -5,045 | -4,073 | 1,057 |
| Net cash used in operating activities | -28,946 | -42,300 | -63,982 |
| Purchases of property and equipment | - | 611 | 1,606 |
| Net cash used in investing activities | - | -611 | -1,606 |
| Repayment of promissory note assumed in business combination | - | - | 2,500 |
| Repayment of term loan-Two Thousand Twenty One Term Loan | - | - | 57,659 |
| Repayment of term loan-Fortress Term Loan | - | 47,720 | 20,000 |
| Repayment of convertible notes | - | - | 10,750 |
| Proceeds from private offerings, net of issuance costs | 4,597 | 2,592 | - |
| Proceeds from term loan - net | - | - | 59,780 |
| Proceeds from public offerings, net of issuance costs | 13,578 | 17,660 | - |
| Proceeds from issuance of convertible notes - net | - | 48,000 | 28,700 |
| Payment of debt issuance costs | - | - | 3,450 |
| Proceeds from revenue interest financing | - | - | 40,000 |
| Payment of debt issuance costs | - | 1,357 | - |
| Proceeds from option and warrant exercises | - | 26 | 213 |
| Proceeds from business combination, net of transaction costs | - | - | 61,652 |
| Proceeds from equity line financing | 795 | 1,007 | - |
| Net cash provided by financing activities | 18,970 | 20,208 | 95,986 |
| Net decrease in cash and cash equivalents and restricted cash | -9,976 | -22,703 | 30,398 |
| Cash and cash equivalents and restricted cash at beginning of period | 15,718 | - | - |
| Cash and cash equivalents and restricted cash at end of period | 5,742 | - | - |
ALLURION TECHNOLOGIES, INC. (ALUR)
ALLURION TECHNOLOGIES, INC. (ALUR)